Pharmacogenetic Testing in Patients With Depression: A Quality Improvement Project

Area of Science:

• Psychiatry
• Pharmacogenomics
• Clinical Outcomes

Background:

• Antidepressants are common first-line treatments for major depressive disorders (MDDs).
• High rates of medication discontinuation occur due to side effects.
• Pharmacogenetic testing (PGx) aids in predicting drug metabolism to reduce trial-and-error prescribing.

Purpose of the Study:

• To evaluate the impact of PGx on MDD remission rates and clinical outcomes.
• Comparison of PGx versus standard of care (SOC) in psychiatric practice.

Main Methods:

• Quality improvement project design.
• Outcomes measured via electronic health record problem status system.
• Patient self-reports and clinician interpretation used; no validated scales employed.

Main Results:

• Standard of care (SOC) group showed higher MDD remission rates (38%) than the PGx group (9.8%).
• The PGx group had a higher incidence of moderate (24.4%) and severe (17.1%) MDD.
• SOC group exhibited more stable problem status (70%) compared to PGx (43.9%).

Conclusions:

• Pharmacogenetic testing (PGx) may hold clinical value for individuals with severe depression.
• Results necessitate cautious interpretation due to methodological limitations.
• Further research with validated scales and controlled designs is recommended.